ARTICLE | Company News
Ipsogen, Institut Gustave Roussy deal
February 1, 2010 8:00 AM UTC
Ipsogen received an option to license exclusive, worldwide rights to the institute's IP covering genomic abnormalities in the tumor suppressor gene TET2. If the option is exercised, Ipsogen plans to ...